Zacks Investment Research
26 Oct 2026, 22:50 UTC · 1h ago
Impact · against what's priced in
The news for Recursion Pharmaceuticals is neutral as it primarily reflects existing analyst consensus for upcoming earnings. While projected revenue growth is high, the information is already integrated into market expectations.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Analysts expect Recursion Pharmaceuticals to report quarterly revenue of $10.92 million, a 110.83% increase year-over-year.
Priced inconsensus estimate for forthcoming earnings report
So whatThis revenue target represents roughly 25% of the $42.82 million full-year projection.
More positive than 78% of claims this week
The company is projected to post quarterly earnings of -$0.24 per share, reflecting year-over-year growth of 33.33%.
Continue reading
5 related stories
The company is projected to see a 110.83% year-over-year increase in quarterly revenue to $10.92 million, though small analyst revisions of 1.41% provide only marginal short-term support.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Priced inanalysts expect in forthcoming earnings report
So whatThe expected quarterly loss is roughly 26% of the projected -$0.93 annual EPS.
More positive than 65% of claims this week
Zacks Consensus EPS estimates for Recursion Pharmaceuticals have increased by 1.41% over the last 30 days.
Priced inanalysis of estimates over the last 30 days
So whatSmall positive revisions generally correlate with short-term price support but are insufficient to move the stock out of its current #3 (Hold) rank.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 64% of ticker scores this week
The stock outperformed the S&P 500 in the latest session and shows significant projected revenue growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
55m ago
—
RXRX hasn't traded since this ran. Last close $3.80 (Oct 26); the reaction starts at the next open.
RXRX chart →
